Loading stock data…
NOVN.SW
CHF 113.56-0.16 (-0.14%)
Market ClosedLast close Apr 27
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally.
Historical Price
Price (Line)
50-Day SMA
200-Day SMA
Whystock Brain
The Narrative
Novartis AG in the Healthcare sector is trading at $113.60. The stock is currently 13% below its 52-week high of $131.00, remaining 7.2% above its 200-day moving average. Technical signals show oversold RSI of 29 and bearish MACD signal, explaining why NOVN.SW maintains its current momentum and trend strength. The Whystock Score of 90/100 reflects a high-conviction bullish alignment.
Ecosystem Influences
Oversold momentum (RSI 29) — potential for technical mean-reversion
Long-term trend bullish (Price vs 200-day SMA)
Macro-economic sensitivity to interest rate and inflation shifts
Loading Financials...
Peer Comparison
JNJUNHPFE
Whystock Valuation Model
Whystock fair value is estimated using a trailing P/E model adjusted for return on equity: Fair P/E = 18 + (ROE × 20). Fair Value = (Current Price ÷ Trailing P/E) × Fair P/E. A base P/E of 18 represents a typical market multiple, scaled upward for companies that earn high returns on equity. The result is a theoretical "normalised" price — not a price target or investment advice. Large deviations are common for high-growth or loss-making companies.
Current PriceCHF 113.56
Potential Upside
17.3%
Whystock Fair ValueCHF 133.18
Price
UndervaluedFair ValueOvervalued
Simplified model based on P/E and ROE. Not a substitute for full valuation analysis. Data may be delayed. See our Terms.
Analyst Consensus21 analysts
Hold
Mean targetCHF 120.74+6.3%
RangeCHF 90.99 – CHF 138.81
Fundamentals
Novartis AG researches, develops, manufactures, distributes, markets, and sells pharmaceutical medicines in Switzerland and internationally. The company offers Entresto, an angiotensin receptorneprilysin inhibitor to treat symptomatic chronic heart f...
Market Cap
Total dollar market value of a company's outstanding shares of stock (Price * Shares).
$220.54B
P/E Ratio
Priced for growth. Investors expect sustained double-digit expansion.
20.60
Beta
Defensive asset. Lower volatility than the S&P 500.
0.52
Div Yield
Strong income play. Yield provides a meaningful total return floor.
319.00%
ROE
Elite ROE. Management converts capital into profit efficiently.
30.81%
Volume
Today's trading volume
677,630
Recent News
Novartis secures pair of regulatory wins for skin disease and malaria treatments
Novartis’ Rhapsido has won approval in Europe, while Coartem Baby has received WHO prequalification.
Novartis AG (NVS): One of the Best Low Risk High Growth Plays on the Market
We just covered the 14 Best Low Risk High Growth Stocks to Buy Right Now and Novartis AG (NYSE:NVS) ranks 7th on this list. Following the successful spin-off of its Sandoz generics division in late 2023, Novartis AG (NYSE:NVS) has transformed into a high-margin, pure-play innovative medicines company that is currently outpacing its peers in […]
Regulatory round-up: Novartis, Sanofi and Arrowhead secure CHMP blessings
The EMA’s CHMP has stated its positive opinions on three drugs for autoimmune, muscle wasting and rare genetic diseases.
Incyte Gears Up to Report Q1 Earnings: What Can Investors Expect?
INCY heads into Q1 earnings with a $1.23 billion revenue view, driven by Jakafi, Opzelura, rising royalties and multiple new launches contributing to revenues.
Novartis Secures Positive EU Backing for SMA Gene Therapy Itvisma
Novartis (NYSE:NVS) said the European Medicines Agency’s Committee for Medicinal Products for Human Use has issued a favourable opinion recommending approval of Itvisma, an intrathecal gene therapy for spinal muscular atrophy (SMA). The recommendation covers use in children aged two and above, as well as adolescents and adults with 5q SMA carrying a bi-allelic mutation in the survival motor neuron 1 (SMN1) gene.